GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

Britons across the nation are experiencing what they're calling 'the worst cold ever', as this winter's illnesses strike hard ...

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

Dr. Kerry-Anne Perkins, a new mom and board-certified OB-GYN shares what parents need to know about RSV and more.

Vermont has the second lowest state fatality rate in the US (141.1 per 100K; Hawaii 111.7/100K). Mississippi (457.4/100K) and ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RS ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

But in 2022, after the pandemic precautions relaxed, cases of influenza and RSV surged. Now it appears whooping cough is back as well: This week, the Washington State Department of Health reported ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

If you’ve had a lingering cough recently, there is a chance the culprit wasn’t Covid-19, flu or RSV, but mycoplasma ...

This treatment enhances babies' immunity against RSV, a virus that poses a serious threat to infant health, particularly in ...